Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older (male or female) who have been diagnosed with a specific stage of liver cancer (called BCLC Stage B hepatocellular carcinoma) and have been referred for a procedure called TACE
- People whose liver tumour measures at least 3 cm across and has been confirmed as a liver cancer lesion (meeting "LI-RADS 5" criteria) by a specialist radiologist using detailed imaging scans
- People whose liver is functioning at a certain level (Child-Pugh-Turcotte score of A or B7) and who have a fully active performance status (Performance Status 0, meaning no limitations on daily activity)
- People who have been fully informed about the research nature of this study and have signed and dated a consent form
- People who are willing and able to follow all study procedures for the full duration of the study
Who may not be able to join:
- People who have an abnormal heart rhythm finding on an ECG test, specifically something called QT prolongation
- People who have been found to have retinopathy (a problem affecting the back of the eye) on an eye examination
- People who are pregnant or breastfeeding at the time of screening — a pregnancy test will be done for women who could potentially become pregnant
- People who have previously had a local treatment to the target liver tumour, or have received systemic (whole-body) therapy targeting that lesion
- People who cannot safely have a contrast-enhanced MRI scan, or who have a metal implant in their liver
- People who have an allergy to a medication called hydroxychloroquine (HCQ), or who have porphyria, uncontrolled psoriasis, or existing retinopathy
- People whose tumour cannot be safely accessed for a biopsy, based on pre-procedure imaging as determined by the treating specialist
- People with serious or unstable medical or psychological conditions that, in the opinion of the research team, could affect their safety or ability to participate fully in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Terence P Gade, MD PhD, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Phone: (215) 823-5800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Local Progression Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.